FIMM Meets Pharma Webinar Series

FIMM Meets Pharma Webinar Series cover image with blue chromosome and FIMM, University of Helsinki and Health Capital Helsinki logos.

 

The Institute for Molecular Medicine Finland (FIMM) has for several years been spearheading Pharma collaborations from the University of Helsinki. We are excited to launch a new "FIMM meets Pharma" webinar series, which aims to showcase the current scientific frameworks and technological capabilities of FIMM, and spark interest with pharmaceutical partners to initiate new projects and collaborations.  The webinar series will showcase some examples of successful research collaboration between our research community and Finnish and international companies. Welcome to join the growing group of satisfied customers and collaborators! 

The events are organized in collaboration with Health Capital Helsinki.

Date and time:

October 28, 16-17:30 EET (HelsinkI)

Programme:

16.00-16.20: Welcome and introduction to FIMM's Digital Diagnostics Programme

Johan Lundin, Research Director, FIMM, University of Helsinki

16.20-16.40: Multiplexed imaging of tumor microenvironment

Teijo Pellinen, Researcher (PhD), FIMM, University of Helsinki

16.40-17.00: AI for prediction of patient outcome and efficacy in molecularly targeted treatments of breast cancer

Dmitrii Bychkov, PhD student (MTech), FIMM, University of Helsinki

17.00-17.15: Q/A and discussion

Moderator: Nina Linder, Senior Researcher, FIMM, University of Helsinki

Registration:

Please register to the event by filling in this e-form by October 27th. Zoom link will be sent to those registered closer to the event.

 

Date and time:

September 29, 16-17:15 EEST (Helsinki)

The webinar will be organized via Zoom.

Speakers:

Research Director Aarno Palotie, Scientific Director of the FinnGen study

Dr. Mark McCarthy, Executive Director Human Genetics Senior Fellow, Human Genetics, Genentech

Dr. Heiko Runz, Medical Director, Head of Human Genetics, Biogen

Programme:

16.00-16.05: Welcome and introduction to FIMM's Genomics Grand Challenge Programme

16.05-16.20: FinnGen study - What, why and how?
Aarno Palotie, Research Director, FIMM, University of Helsinki

16.20-16.40: Leveraging genetics in drug development
Dr. Mark McCarthy, Executive Director Human Genetics Senior Fellow, Human Genetics, Genentech

16.40-17.00: Opportunities for FinnGen and the Finnish ecosystem to contribute to drug discovery and development
Dr. Heiko Runz, Medical Director, Head of Human Genetics, Biogen

17.00-17.15: Q/A and discussion

FIMM has close connections to the Helsinki University Hospital and extensive experience with deep molecular profiling and machine-assisted analysis of patient samples. In recent years we have established collaborative research projects with several pharmaceutical partners. In this webinar, we will feature our collaboration with Novartis.

Date and time:

June 22, 16:00 - 17:30 EEST (Helsinki)

The webinar will be organized via Zoom.

Speakers:

Research Director Caroline Heckman (FIMM), Professor Kimmo Porkka (HUS), and VP, Global Head of Biomarker & Diagnostic Celine Pallaud (Novartis)

Programme:

16.00-16.05: Welcome and introduction to FIMM's Functional Precision Medicine in Cancer Grand Challenge Programme
Dr. Caroline Heckman, Research Director, FIMM, University of Helsinki

16.05-16.20: Precision medicine in practice: Helsinki hematology experience
Professor Kimmo Porkka, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center

16.20-16.35: Correlative studies in hematology for biomarker discovery
Dr. Caroline Heckman, Research Director, FIMM, University of Helsinki

16.35-16.50: Advancing precision medicine through industry-academic partnerships
Dr. Celine Pallaud, VP, Global Head of Biomarker & Diagnostic, Novartis

16:50-17:05 Q/A and discussion

17:05-17:30 Possibility to join breakout rooms hosted by our speakers and FIMM technology and administrative experts to ask questions and/or learn more about the following themes:

  1. Translating research to patient care
  2. Applying FIMM technologies for precision medicine: Single cell analytics
  3. Applying FIMM technologies for precision medicine: Drug sensitivity testing 
  4. Examples of blood cancer research to advance precision medicine
  5. Legal challenges and administrative aspects of establishing collaborations between industry and academic researchers

Finland and FIMM as partners with industry to harness the potential of human genetics, cancer precision medicine and digital pathology

Research at FIMM aims to bring health benefits to people and populations. This is achieved through understanding molecular mechanisms of disease linked to registry data, biobanked samples, and individual’s health & disease profiles. Pharma collaborations play a central role in delivering on these translational aims. 

To advance our partnering with Pharma, FIMM hosted a well-received FIMM-meets-Pharma meeting in 2016. This new FMP Webinar Series aims to reinvigorate these activities, to reach new academic-industry partnering horizons. 

Date and time:

20 May 2021, 16:00-17:15 EET (Helsinki)

Program:

 

16:00-16:05 - Introducing the new webinar series

16:05-16:15 - Partnerships to accelerate Precision Medicine

Jonathan Knowles, Professor and multi-company board member

16:15-16:25 - FIMM & Finland: an ideal setting for academic-industry collaboration 

Mark Daly, Director of FIMM

16:25-16:55 - Panel discussion and Q/A

16:55-17:05 Next webinars (Caroline Heckman, Aarno Palotie & Nina Linder)

17:05-17:15 Polling and closing words